Startup Arcturus Therapeutics this week announced that it has acquired Marina Biotech’s unlocked nucleobase analog intellectual property in a move the company said would give it freedom to operate in the RNAi drugs space.
The transaction also represents Marina’s latest step toward monetizing its assets following a shutdown last summer. With this latest transaction, however, the company said it has gained much-needed breathing room as it tries to resume operations.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
